Literature DB >> 24888811

How low should we go? The search for balance in management of small human epidermal growth factor receptor 2-positive breast cancers.

Katherine E Reeder-Hayes1, Lisa A Carey2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24888811     DOI: 10.1200/JCO.2014.55.7249

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  2 in total

1.  [Is the waiver of chemotherapy for small, node-negative breast cancer justified? ].

Authors:  Marie-Luise Sautter-Bihl; Felix Sedlmayer
Journal:  Strahlenther Onkol       Date:  2015-01       Impact factor: 3.621

2.  Disparities in Use of Human Epidermal Growth Hormone Receptor 2-Targeted Therapy for Early-Stage Breast Cancer.

Authors:  Katherine Reeder-Hayes; Sharon Peacock Hinton; Ke Meng; Lisa A Carey; Stacie B Dusetzina
Journal:  J Clin Oncol       Date:  2016-04-11       Impact factor: 44.544

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.